Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for muscle relaxant reversal in preterm neonates
NCT04566796Unknown
- Sponsor
- Alexandria University
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Alexandria University. Primary endpoints: Time to reach TOF ratio ≥ 0.9 and Time to complete recovery. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04566796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566796.